KYMR: Kymera Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,624.90
Enterprise Value ($M) 1,504.65
Book Value ($M) 835.62
Book Value / Share 12.87
Price / Book 1.94
NCAV ($M) 367.85
NCAV / Share 5.66
Price / NCAV 4.42

Profitability (mra)
Return on Invested Capital (ROIC) -0.24
Return on Assets (ROA) -0.26
Return on Equity (ROE) -0.31

Liquidity (mrq)
Quick Ratio 7.53
Current Ratio 7.53

Balance Sheet (mrq) ($M)
Current Assets 510.27
Assets 978.03
Liabilities 142.42
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 47.07
Operating Income -256.71
Net Income -223.86

Cash Flow Statement (mra) ($M)
Cash From Operations -194.50
Cash from Investing -404.08
Cash from Financing 608.85

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-10 13G/A Wellington Management Group Llp 8.20 14.92
11-14 13G/A Avoro Capital Advisors LLC 9.99 105.30
11-14 13G/A Price T Rowe Associates Inc /md/ 10.30 10.77
11-14 13G/A Atlas Venture Fund X, L.P. 6.40 -16.00
11-12 13G Fmr Llc 7.93 117.64
08-22 13D/A Baker Bros. Advisors Lp 9.30 0.06

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 103,096 396,192 26.02
2025-04-16 180,075 646,661 27.85
2025-04-15 78,948 332,836 23.72
2025-04-14 119,453 566,016 21.10

(click for more detail)

Similar Companies
KLTO – Klotho Neurosciences, Inc. KOD – Kodiak Sciences Inc.
KROS – Keros Therapeutics, Inc. LGND – Ligand Pharmaceuticals Incorporated
LNTH – Lantheus Holdings, Inc.


Financial data and stock pages provided by
Fintel.io